End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
17.77 MXN | -4.51% | +6.53% | +25.49% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company has a low valuation given the cash flows generated by its activity.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+25.49% | 1.03B | B+ | ||
+40.73% | 739B | C+ | ||
+32.83% | 598B | B | ||
-6.30% | 353B | C+ | ||
+15.15% | 318B | B- | ||
+4.05% | 285B | C+ | ||
+15.00% | 240B | B+ | ||
+9.78% | 210B | B- | ||
-5.52% | 206B | A+ | ||
+6.17% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LAB B Stock
- Ratings Genomma Lab Internacional, S.A.B. de C.V.